Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Apr 30, 2019
Appendix 4C - quarterly
Apr 29, 2019
Notice of Annual General Meeting/Proxy Form
Apr 26, 2019
Appendix 4G
Apr 26, 2019
Annual Report to shareholders
Apr 26, 2019
Update on development plan for NNZ-2591
Mar 28, 2019
Neuren's Rett syndrome Phase 2 trial published in Neurology
Feb 27, 2019
Fundamentals strong as Neuren advances neuroscience pipeline
Feb 27, 2019
Preliminary Final Report and statutory accounts
Feb 18, 2019
NNZ-2591 positive effects in Phelan-McDermid syndrome model
Feb 04, 2019
Plans for Phase 3 trial in Rett syndrome
Previous
1
2
3
4
Next
